Clinical trials: Graft vs Host Disease
Graft Versus Host Disease
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD
Graft versus host disease is a serious and often life-threatening complication in allogeneic haematopoietic stem cell transplantation.
- Trial name
- NCT02824653
- Testing
- Mesenchymal Stem Cells
- Where
- Pakistan
- Volunteers
- 10 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Hematologic Malignancies, Graft-Versus-Host Disease
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation…
- Trial name
- NCT02342613
- Testing
- Activated PTCy-MILs
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft Versus Host Disease, Ocular Surface Disease
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD).
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease
- Trial name
- oGVHD (NCT03591874)
- Testing
- Brimonidine Tartrate
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ocugen
Chronic Radiation Dermatitis
Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury
Radiotherapy, an essential modality in cancer treatment, frequently induces a fibrotic process in the skin which can lead to increased risk of malignancy, poor wound healing, pain and limitation of movement, and permanent loss of…
- Trial name
- NCT01910818
- Testing
- Fractional CO2 laser treatment, No treatment
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021…
- Trial name
- NCT01677780
- Testing
- RO5045337
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Refractory Chronic Graft Versus Host Disease (cGVHD)
Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
The present project is a prospective, multicenter, non-randomized, phase II trial which aims to evaluate the clinical impact and the safety of extracorporeal photopheresis (ECP) using the Theraflex system in patients with…
- Trial name
- NCT03083574
- Testing
- Photopheresis Theraflex ECP™
- Where
- 8 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Jules Bordet Institute
Fatigue, Graft Vs Host Disease
Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain.
Patients undergoing allogenic stem cell transplantation are regularly followed up in the outpatient clinic at Karolinska University Hospital.
- Conditions
- Fatigue, Graft Vs Host Disease, Cognitive Dysfunction
- Trial name
- NCT07365696
- Testing
- PET investigation
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Inborn Errors of Immunity
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)
- Trial name
- NCT06199427
- Testing
- Cyclophosphamide, Ruxolitinib
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Graft-versus-host-disease, Prophylaxis
Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT
Low dose Rabbit Antithymocyte Globulin plus Low-dose post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplantation for patients with hematologic…
- Trial name
- ATG/PTCy (NCT03395860)
- Testing
- ATG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Low Back Pain, Chronic
Person-Centered Lifestyle Redesign in Chronic Low Back Pain
This study is designed to examine the effects of a person-centered lifestyle intervention on pain, occupational performance, quality of life, disability, physical activity levels, and mental status in individuals with chronic low…
- Trial name
- NCT07163546
- Testing
- Lifestyle intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Hacettepe University
Graft-versus-host-disease, Stem Cell Transplant Complications
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
This is multicenter investigator-initiated randomized open-label phase II clinical trial to compare prophylaxis of graft versus host disease treated with tacrolimus and mycophenolate mofetil versus ruxolitinib after…
- Conditions
- Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- PTCyRuxo (NCT04669210)
- Testing
- Ruxolitinib, Tacrolimus, Mycophenolate Mofetil
- Where
- 2 sites in Russia
- Volunteers
- 128 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard…
- Trial name
- NCT00928018
- Testing
- Sirolimus, Methotrexate, Tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute
Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
The purpose of this study is determine the highest dose of bortezomib, a new drug for graft-versus host disease prevention, that can be given in combination with sirolimus and Tacrolimus, without causing severe side effects.
- Conditions
- Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
- Trial name
- NCT00670423
- Testing
- Tacrolimus, Sirolimus, Bortezomib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jennifer E. Schwartz
Graft-Versus-Host Disease(GVHD)
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.
Study Title: A Study on the Effects and Mechanisms of Omega-3 Polyunsaturated Fatty Acids on Acute Graft-Versus-Host Disease (aGVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation Study Type: Open-label, randomized…
- Trial name
- NCT07162688
- Testing
- Omega-3 Lipid Emulsion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University
Graft Vs Host Disease
Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kg
Allogeneic hematopoietic cell transplantation (HSCT) is a worldwide recognized therapy for several hematologic malignancies; a modality extensively used around the world due to its effectivity; however, an HLA-matched sibling or…
- Trial name
- NCT05780554
- Testing
- Cyclophosphamide
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Centro de Hematología y Medicina Interna
Blood Stem Cell Transplant Failure
Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)
Samples of blood and urine will be analyzed for biomarkers to check their predictivity of Graft-versus-Host Disease (GVHD) outcomes.
- Trial name
- NCT01569373
- Where
- United States
- Sponsor
- Mayo Clinic
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
Chronic GVHD
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of…
- Trial name
- NCT01106833
- Testing
- Sirolimus + calcineurin inhibitor + prednisone, Sirolimus + prednisone
- Where
- 31 sites in United States
- Volunteers
- 151 people
- Sponsor
- Medical College of Wisconsin
Acute GVHD
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined…
- Trial name
- NCT02806947
- Testing
- Sirolimus, Prednisone
- Where
- 21 sites in United States
- Volunteers
- 127 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.